Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 

Cost-Effectiveness and Guidelines for Opioid Substitution Treatment

Examine the cost-effectiveness of SROM, hydromorphone, diacetylmorphine, and fentanyl in opioid use disorder, and describe the evidence-based guidelines for the use of these treatments
Lit review | 2021
Clinical guidance, Evidence base, Safer supply, About prescribers, Substitution/OAT

Wound Bed Preparation 2021

To present the 2021 update of the Wound Bed Preparation paradigm
Guidelines | 2021
Clinical guidance, Wrap-around services, About prescribers, Chronic pain, Injecting drugs

Boîte à outils pour la mise en place d’un site répondant à un besoin urgent en matière de santé publique (SBUSP)

Guide or handbook | 2021
Overdose, Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, SCS/OPS

Trauma Informed Practice and the Opioid Crisis: A Discussion Guide for Health Care and Social Service Providers

Research has shown that the vast majority of individuals who experience problems with opioid misuse and addiction have current or past experiences of trauma and violence.
Guide or handbook | 2018
Clinical guidance, Harm reduction, Sex/Gender , Mental health

Treatment Approaches for Users of Methamphetamine: A Practical Guide for Frontline Workers

Alcohol and other drug (AOD) workers from a variety of service settings are now frequently required to respond to methamphetamine users who are experiencing the harmful effects of methamphetamine, goi
Guide or handbook | 2008
Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, Stimulants, Transitions in care/treatment

Québec Guide to Improving Practices in the Management of Opioid Use Disorder

Guidelines | 2020
Clinical guidance, Harm reduction, Safer supply, About prescribers, Substitution/OAT, Transitions in care/treatment

Understanding the behavioural determinants of opioid prescribing among family physicians: a qualitative study

The aim of this work was to understand (1) the perspectives of family physicians (FPs) as it relates to opioid prescribing, and (2) the perceived barriers and enablers to guideline-adherent opioid pre
Original research | 2019
Clinical guidance, Policy/Regulatory, Hesitancy of prescribers , Safer supply, About prescribers, Barriers and enablers, Chronic pain

Best Practices for Health and Social Service Providers Working with People Who Use Drugs

Short visual summary of Blood Ties' "Don't Be An A**hole" best practices report
Infographic | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma

Don't Be An A**hole: Best Practices for Health and Social Service Providers Working with People Who Use Drugs

Outlines key themes found among people who use drugs about their experiences with various health and social service agencies and providers in Whitehorse
Report | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma

COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists

Guidelines | 2020
Clinical guidance, About pharmacists, About prescribers

Pharmacists Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies: Notification to all pharmacists in the Vancouver Coastal Health (VCH) region

Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs

Prescriber Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies: Notification to All Prescribers in the Vancouver Coastal Health (VCH) Region

Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs

A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting

Very little is known about the value of UDS, the optimum screening frequency in general, or its specific use for buprenorphine treatment in primary care.
Original research | 2021
Clinical guidance, About prescribers, Outcomes, Substitution/OAT, Diversion

Ketamine for the treatment of acute pain

Guidelines | 2021
Clinical guidance, About prescribers, Chronic pain

Opioid Agonist Treatment (OAT) Guidance During the COVID-19 Pandemic

Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.
Guidelines | 2020
Clinical guidance, Harm reduction, About pharmacists, About prescribers

5 Things You Should Know About Safer Opioid Supply Programs

Commentary | 2021
Clinical guidance, Harm reduction, Hesitancy of prescribers , Safer supply, About pharmacists

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder

Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this in
Original research | 2019
Clinical guidance, Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Substitution/OAT, Injecting drugs

Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction

To raise awareness of alternative techniques that can facilitate buprenorphine-naloxone treatment for opioid use disorder.
Original research | 2020
Clinical guidance, Harm reduction, About prescribers, Substitution/OAT

Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review

Shared decision-making (SDM) is an approach to clinical decision-making that includes patients' values and preferences during health-related decisions.
Scoping review | 2021
Clinical guidance, About prescribers, About PWUD

Stakeholder preferences for supervised consumption site design, staff, and ancillary services: A scoping review of feasibility studies

We conducted a scoping review of feasibility studies reporting on preferred SCS design characteristics, staffing models and ancillary services.
Scoping review | 2021
Overdose, Clinical guidance, About prescribers, About PWUD, Illegal drugs, SCS/OPS

Affiner votre recherche

Mots clés
Format
Région